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ABSTRACT
The amine-borane adducts of cyclohexylamine and toluidine were observed
to be potent hypolipidemic agents in mice, I.P. and rats orally at 8
mg/kg/day lowering both serum cholesterol and triglyceride levels after
14-16 days. These compounds were able to lower tissue lipids including
the cholesterol content of the aorta wall. The agents successfully
lower VLDL- and LDLocholesterol content while elevating HDL-cholesterol
content significantly. The agents also modulate lipid regulatory enzyme
activities in a manner to reduce liver lipid levels. These studies
demonstrate that the nitrogen atom does not have to be apart of the
aromatic ring as in heterocyclic-amine borane to afford good
hypolipidemic activity in rodents.
INTRODUCTION
Previously we have examined a number of amine-cyanoboranes[l] amine-
carboxyboranes and their amides and esters[2-5], di- and triopeptide
boranes[6], heterocyclic-amine boranes[7], polyborate salts[8], choline
and thiocholine boranes[9], phosphoacetate boranes[10] and
deoxyribonucleoside cyanoboranes[ll]. These agents were effective in
rodents at 8 mg/kg/day, significantly lowering both serum cholesterol
and triglyceride levels after 14-16 days. Cholesterol levels were
lowered in rat VLDL and LDL fractions while the HDL cholesterol levels
were markedly elevated. The mode of action of these derivatives was to
acclerate bile cholesterol excretion and alteration of regulatory enzyme
activities involved in de novo lipid synthesis. Furthermore, sub-acute
toxicity studies in mice indicated no organ specific toxicity and mean
survival doses were high[12]. Thus, we have decided to examine a series
cyano- and carboxyborane adducts of cyclohexylamine and toluidine for
their hypolipidemic activity in rodents. These studies should determine
if the nitrogen atom is necessary in the aromatic ring to maintain
activity as a hypolipidemic agent in rodents.
MATERIALS and METHODS
Source of compounds
All of the compounds were synthesized previously and chemically and
physically charectezized[13] cyclohexylamine-cyanoborane _i,
cyclohexylamine-carboxyborane 2, N-methylcyclohexylamine-carboxyborane
3_, N-ethylcyclohexylamine-carboxyborane 4, N,N-dimethylcyclohexylamine-
carboxyboranes 5, 2-methylcyclohexylamine-carboxyborane 6, 3-
methylcyclohexylamine-carboxyborane 7, 4-methylcyclohexylamine-
carboxyborane 8, N-ethylcyclohexylamine-cyanoborane 9, N-
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methylcyclohexylamine-cyanoborane IO, N,N-dimethylcyclohexylamine-
cyanoborane ii, 2-methylcyclohexylamine-cyanoborane 12, 3-
methylcyclohexylamii’e-cyanoborane 13, 4- methylcyclohexylammine-
cyanoborane 14, 2,3-dimethylcyclohexylamineocyanoboranes 1__5, -
toluidine-cyanoborane 16, N-toluidine-cyanoborane 17, -toluidine-
cyanoborane 18, and -anisidine cyanoborane 19. All isotopes were
purchased from New England Nuclear. Substrates and co-factors were
obtained from Sigma Chemical Co. Sprague Dawley male rats were obtained
from Charles River Laboratory. CFI mice were obtained from Jackson
Laboratory. Animals were maintained in light cycles of 12 h at 22C.
Rats were maintained in individual wire cages and mice were housed
three/plastic cage. Food (Agway/Prolab Animal Diet) and water were a__d
libitum.
Normolipidemic studies
For structure activity studies, CFI male mice (-28g) were administered
amine-borane adducts of cyclohexylamine and toluidine in i CMC at 8
mg/kg/day, I.P. Blood samples were obtained on days 9 and 16 between
7"30 and 8"30 a.m. Daily dosing of the agents was between 9"00 and I0"00
a.m. the serum was obtained by centrifuging the blood for i0 min. at
3500 g. The serum cholesterol levels were determined by a modification
of the procedure Lic.bermann-Burchard reaction [14]. Serum triglyceride
were determined using a commercial kit [Boehringer Mannheim
Diagnostics]. Sprague Dawley male rats (-230 g) were administered orally
Compounds 7, 9_ or 18 at 8 mg/kg/day, for two weeks. Weekly blood
samples were obtained by tail vein bleeding.
Animal weight, organ weight and food consumption
Control and treated normolipidemic Sprague Dawley male rat(-230g)
weights were obtained and expressed as a percentage of the initial body
weight (week zero). Food consumption (gm/day/rat) was noted for two
weeks for control and treated rats[15].
Tissue lipid levels
Normolipidemic Sprague Dawley male rats (-230 g) which were treated
orally for two weeks with compound 7, 9_ or 1__8 at 8 mg/kg/day, were
sacrificed and tissue samples of the liver, small intestinal mucosa and
aorta were removed. A 24 hr fecal sample was also obtained. A i0
homogenate in 0.25 M sucrose + 0.001 M EDTA, pH 7.2, was prepared for
each tissue. An aliquot (2 ml) of the homogenate was extracted[ 16-17]
and the number of mg of lipid extracted was weighed. The lipid residue
was taken up in methylene chloride and the levels of cholesterol [14],
triglycerides neutral lipids[18] and phospholipids[19] were
determined. Protein content of the whole homogenate was determined[20].
Serum lipoprotein fractions
Normolipidemic Sprague Dawley male rats(-230g) treated for two weeks
with compounds 7, _9 or 18 at 8 mg/kg/day, orally were anesthesized with
ether and blood (-I0 ml) was collected from the abdominal vein. Serum
was separated from whole blood by centrifugation at 3500 rpm. Aliquots
of the serum were separated into chylomicrons, VLDL, HDL and LDL by
ultracentrifugation as modified for normal rats[21o22]. Each of the
fractions was analyzed for cholesterol, triglyceride, neutral lipids,
phospholipid and protein levels.
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Enzymatic studies
In vitro enzymatic studies were performed using i0 homogenates of liver
mucosa from normolipidemic Sprague Dawley male rats (-280g). The liver
homogenates were prepared in 0.25 M sucrose + 0.001 M
(ethylenedinitrilo)tetraacetic acid [EDTA], pH 7.2. Acetyl coenzyme A
synthetase[23] and adenosine triphosphate dependent citrate lyase
activities[24] were determined spectrophotometrically at 540 nm as the
hydroxylamate of acetyl coenzyme A formed after 20 min at 37C.
Cholesterol-7-hydroxylase activity was determined using [1,2-
3H]cholesterol (60 mCi/mmol)[25], and acyl CoA cholesterol acyl
transferase activity was determined using [l-14C]oleic acid (56.7
mCi/mmol)[26]. Cholesterol synthesis was measured using [I-14C] acetyl
CoA (62 mCi/mmol) and a post-mitochondrial supernatant (9000 g x 20 min)
which was incubated for 60 rain at 37C [27]. The digitonide derivative
of cholesterol was isolated and counted [2_8]_ Cholesterol ester
hydrolase activity was determined using 1-14C cholesterol oleate [56.6
mCi/mol] [29].
For acetyl coenzyme A carboxylase activity, the enzyme had to be
polymerized for 30 rain at 37C and then the assay mixture containing
sodium 14C-bicarbonate (41.0 mCi/mmol) was added and incubated for 30
min at 37C with test drugs[30], s__n-Glycerol-3-phosphate acyl
transferase activity was determined with s__n-glycerol-3ophosphate [L-2-
3H(N)] (7.1 Ci/mmol) with the microsomal fraction of liver homogenates.
The reaction was terminated after 60 rain and the lipids were extracted
with chloroform/methanol (2"1) containing i HCI and counted[31].
Phosphatidylate phosphohydrolase activity was measured as inorganic
phosphate released after 60 min[32]o The released inorganic phosphate
after color development with ascorbic acid and ammonium molybate was
quantitated at 820 nm. Hepatic lipoprotein lipase was determined using
glycerol-triol4C-palmitate [64 mCi/mol] emulsified with lecithin by the
method of Chair et alo [33]. Protein content of the liver homogenates was
determined[ 20
Data displayed in Tables 1-5 represent means + standard deviations. The
Student’s "t" test was applied between control groups and the individual
drug treatment groups using the raw data. The analysis of variance
(ANOVA) was applied among test drugs and is reported in the text only.
RESULTS
Selected carboxy- apd cyanoborane adducts of cyclohexylamine and
toluidine were shown to be significantly active in the structure
activity study in mice at 8 mg/kg/day. In comparison to the standards
lovastatin and clofibrate, compounds i_, 2, 5, 7_, 8, 9, I__Q0, 1_/3, 1__6, 1_/7,
and 1__8 lowered serum cholesterol by 23% at 8 mg/kg/day on day 16. Serum
triglyceride level on day 16 were reduced by compound 7_, 8, 9, 1_/7 and 1__8
by 27% at 8 mg/kg/day I oP.
Three compounds 7, _9 and 1__8 were selected as being representative
compounds to further study in rats their hypolipidemic action [Table 2].
In rats at 8 mg/kg/day, compound 9 lowered serum cholesterol levels 32%
after 14 days administration orally, whereas compounds _7 and 1__8 caused
at 24-25% reduction. Nevertheless, these compounds were more potent
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Table i" In Vivo Hypolipidemic Activity of Carboxy- and Cyanoborane
Adducts of Cyclohexylamine and Toluidine in CF1 Male Mice at 8
mg/kg/day, I.P. for 16 days.
N=6 Percent of Control (X _+ S.D.)
Compound Day 9 Day 16 Day 16
Serum Serum Serum
Cholesterol Cholesterol Triglyceride
85+/-4 65+/-2* 100+/-4
2 110+6 68+4* 77+5
3 89+4 79+1" 84+11
4 90+2 83+8 90+5
5 82+4 74+9* 82+15
6 91+8 84+2 78+9
87+/-2 59+/-3* 54+/-10"
8 79+4 73+2* 72+8*
9 82+.3 62+5* 66+7*
i0 90+9 69+6* 74+6*
iia 73+3*
12 76+6* 78+4* 84+5
13 83+3 68+6* 84+6
14 58+3* 83+3* 99+5
15 54+-5* 84+1" 112+9
16 73+2* 67+4* 84+14
17 90+2 77+5* 73+14"
1__8 81+/-3 76+/-4* 61+/-15"
1__9 87+/-3 87+/-3* 78+/-5*
Controlb lOOq-5e I00+7 f lO0+llg
Lovastatinc 85+4 82+5* 86+7
Clofibrated 87+6 78+6* 75+6*
Dosed at 4 mg/kg/day, toxic
i CMC
Dosed at 8 mg/kg/day
Dosed at 150 mg/kg/day
125 mg/dL serum cholesterol
128 mg/dL serum cholesterol
137 mg/dL serum triglyceride
p _< 0.001, Student’s ""
test
than lovastatin at 8 mg/kg/day, gemfibrozil at 90 mg/kg/day or
clofibrate at 150 mg/kg/day in lowering serum cholesterol levels after
14 days. Compound . also most effectively lowered serum triglyceride
levels 29 by day 14 yet compounds 7 and 1__8 only caused 21 reduction.
None of the compounas were as effective as gemfibrozil at 90 mg/kg/day
with a 38 reduction of serum triglyceride levels after 14 days.
However, the compounds at 8 mg/kg/day were more effective than
lovastatin at 8 mg/kg/day and approximately equal to clofibrate at 150
mg/kg/day. Daily food consumption and total body weight of the treated
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animals were significantly no different than the control group for 14
days.
Table 2" fn Vivo Hypolipidemic Activity of Carboxy- and Cyanoborane
Adducts of Cyclohexylamine and Toluidine in Sprague-Dawley Male Rats at
8mg/kg/day Orally for 14 Days.
N=6 Percent of Control (X_+S.O.)
Compound Fooda Day 7 Day 14
# Consumption Cholesterol Triglyc.e..ride Cholesterol Triglyceride
7 105+6 100+9 72+7" 75+10 79+_7
102+/-7 118+/-6 56+/-4* 68+/-8* 71+/-7
18 100+7 87+9 71+4 76+7 79+4
Controlb 100+6 100+6 f lO0+4g 100+6h 100+5 i
Lovastatinc 85+4 91+5 82+5 86+7
Gemfibrozild 91+5 91+5 82+7 62+5
Clofibratee 89+/-7 83+/-6 86+/-5 74+/-7
Control 22.1+_1.3 g/day/rat
I CMC
Dosed at 8 mg/kg/day
Dosed at 90 mg/kg/day
Dosed at 150 mg/kg/day
73 mg/dL total serum cholesterol
75 mg/dL total serum cholesterol
iii mg/dL serum triglyceride
112 mg/dL serum triglyceride
p _< 0.001, Student’s "." test
Further tissue lipid extraction studies showed that in rats treated 14
days with compounds 7, _9 or 1__8 [Table 3], liver, small intestinal mucosa
and aorta lipid content was reduced. The triglyceride content was
reduced more consistently than the cholesterol content in all three
tissues. In the aorta tissue neutral lipids and phospholipid content
was also reduced after 14 days treatment. Protein and cholesterol
content of the aorta tissue was reduced after treatment with compound 9.
Total lipid excretion into the feces was not affected by treatment with
the compounds. Fecal triglycerides were elevated significantly by all
three compounds; ho.ever, phospholipids excretion was reduced [Table 3].
Examination of the lipid content of the rat lipoproteins after 14 days
administration showed that all three compounds lowered cholesterol
content in the chylomicron and the LDL fraction. The HDL cholesterol
content was significantly elevated 2 to 3 fold [Table 4] by all three
compounds. Triglyceride content was elevated in the chylomicron
fraction after treatment with compounds 9_ and 1__8. Triglyceride content
was elevated in the VLDL fraction after treatment with compound 7. HDL
triglyceride content was elevated by treatment with compounds 7 and 9.
Neutral lipid content of the lipoprotein fractions was not affected by
any of the compounds. Phospholipid content of VLDL fraction was reduced
by all three compounds while phospholipid content of LDI fraction was
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Table 3 In Vivo Effects of Carboxy- and Cyanoborane Adducts of
Cyclohexylamine and Toluidine on Tissue Lipids in Sprague-Dawley Male
Rats After 14 Days at 8 mg/kg/day, Orally
N=8 Percent of Control (X _+ S.D.)
Mg of Lipid Cholesterol Triglycerides Neutral Phospho- Protein
Extracted
Liver
Control i00 + 4a i00 + 5b
7 86+6 93+5
9 86 + 2 102 + 8
18 96 + 3 109 + 6
Small Intestine
Control i00 + 8g i00 + 7h
7 76 + ii* 94 + 6
9 93 + 16 117 + 7
18 88 + 7 112 + 8
Aorta
Control i00 + 4m IC0 + 5n
7 88 + 12 112 + 6
9 66 + 2* 79 + 4*
18 i01 + 12 i01 + 5
Feces
Control I00 + 8 s 1O0 + 6 t
7 99+3 87+7
9 I01 + I0 95 + 9
18 104 + 9 87 + 8
Lipids lipids
I00 + 7 c I00 + 6d i00 + 7e i00 + 6f
64 + 5* i01 + 6 104 + 8 81 + 5
88 + 6 97 + 6 104 + 5 104 + 6
164 + 7* 98 + 5 91 + 8 Ii0 + 8
i00 + 6 i i00 + 6J i00 + 6k I00 + 71
55 + 4* 105 + 8 93 + 6 117 + 5
67 + 5* 98 + 6 79 + 4* 115 + 5
87 + 6 91 + 5 66 + 5* 119 + 5
i00 + 6 i00 + 5P i00 + 6q I00 + 6r
86 + 4 58 + 4* 91 + 6 94 + 6
81 + 4* 49 + 5* 82 + 7 65 + 6*
99 + 6 89 + 5 54 + 5* 89 + 5
I00 + 6u I00 + 8v i00 + 8w i00 + 6x
148 + 9* 99 + 7 57 + 5* 104 + 6
155 + 8* 97 + 8 65 + 5* 115 + 6
173 + 8* i00 + 7 45 + 4* ii0 + 5
per gram wet tlssue
a 50.5 mg lipid
b 9.18 mg cholesterol
c 6.37 mg triglyceride
d 15.70 mg neutral lipid
e 27.19 mg phospholipid
f 12.02 mg protein
g 68.20 mg lipid
h 12.02 mg cholesterol
i ii.20 mg triglyceride
J 16.98 mg neutral lipid
k 20.06 mg phospholipid
1 42.0 mg protein ,
p <_ 0.001, Students "." test
m 67.5 mg lipid
n 5.77 mg cholesterol
o 9.85 mg triglyceride
P 15.28 mg neutral lipid
q 28.8 mg phospholipid
r 11.71 mg protein
s 11.58 mg lipid
t 2.84 mg cholesterol
u 1.86 mg triglyceride
v 3.39 mg neutral lipid
w 5.70 mg phospholipid
x 6.99 mg protein
elevated approximately two fold. The protein content of the chylomicron
fraction was reducea after 14 day treatment.
The mode of action of the derivatives on rate limiting enzymes involved
in liver lipid metabolism showed that the compounds were not HMG-CoA
reductase inhibitors. Rather these compounds reduced the activites of
cytoplasmic acetyl CoA synthetase and ATP-dependent citrate lyase.
Compound 7 and _9 caused a moderate reduction of Ii-18 in acyl CoA
cholesterol acyl transferase activity. Neutral cholesterol ester
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Table 4" In Vivo Effects of Carboxy- and Cyanoborane Adducts of
Cyclohexylamine and Toluidine on the Lipid Content of Serum Lipoproteins
in Sprague Dawley Male Rats After 14 Days at 8mg/kg/day, Orally
N=4 Percent of Control (X + S.D.)
Cholesterol Triglycerides Neutral Phosphoo
Lipids lipids
Chylomicron
Control I00 + 6a I00 + 7b
7 67 + 5* 105 + 7
9 67 + 4* 158 + 8*
1__8 50 + 6* 136 + 9*
VLDL
Control I00 + 4f I00 + 5g
7 104 + 5 123 + 6
9 118 + 5 99 + 5
18 92 + 4 91 + 8
LDL
Control i00 + 5k i00 + 61
7 65 + 5* 114 + 6
9 50 + 4* i01 + 7
18 63 + 4* ii0 + 6
HDL
Control I00 + 6P i00 + 7q
7 348 + i0" 127 + 5*
9 371 + 9* 116 + 6
18 235 + 9* 129 + 6*
Protein
i00 + 7 c i00 + 6d i00 + 5e
92 + 5 86 + 5 79 + 5
96 + 6 85 + 6 81 + 6
91 + 6 104 + 6 80 + 7
I00 + 7h i00 + 7i I00 + 5J
105 + 6 62 + 5* 107 + 6
107 + 6 44 + 4* 76 + 6*
107 + 5 43 + 4* 93 + 5
i00 + 6m i00 + 6n I00 + 8
98 + 7 202 + 7* 89 + 6
i00 + 7 182 + 8* 133 + 7*
99 + 6 214 + 8* 96 + 8
i00 + 6r i00 + 7 s i00 + 6 t
93 + 4 ii0 + 7 166 + 6*
89 + 5 107 + 6 166 + 6*
92 + 6 81 + 7 167 + 5*
337 I.tg cholesterol/mL serum
420 g triglyceride/mL serum
67 Bg neutral lipid/mL serum
149 g phospholipid/mL serum
184 g protein/mL serum
190 Bg cholesterel/mL serum
22 g triglyceride/mL serum
98 g neutral liFid/mL serum
26 g phospholipid/mL serum
50 g protein/mL serum
<_ 0.001, Student’s ""
test
k 210 tg cholesterol/mL serum
1 45 Bg triglyceride/mL serum
m I0 tg neutral lipid/mL serum
n 41 tg phospholipid/mL serum
o 122 Bg protein/mL serum
P 544 tg cholesterol/mL serum
q 630 g triglyceride/mL serum
r 27 tg neutral lipid/mL serum
s 153 tg phospholipid/mL serum
t 657 tg protein/mL serum
hydrolase activity was reduced by compound _7 by 44, but the other two
compounds only afforded 12-15 reduction. Cholesterol-7-hydroxylase
activity was significantly elevated by all three compounds. Acyl CoA
carboxylase activity was suppressed 17 by compound 7_ and 29o by
compounds _9 and _18. s__n-Glycerol-3-phopshate acyl transferase activity
was reduced 15% by compound 9 and 19% by compound 1__8. Phosphatidyate
phosphohydrolase activity was reduced markedly 76% by compound 7, 82% by
compound 9 and 88% by compound 1__8. Hepatic lipoprotein lipase activity
was reduced 29% by compound _7 and 19% by compound 1__8.
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Table 5" In Vitro Inhibtion of Liver Lipid Enzyme Activies by
and Cyanoborane Adducts of Cyclohexylamine and Toluidine
Percent of Control (X +/- S.D.)
N=6 Compound 7
Enzyme Assay Control 25tM 50tM 100[M
Carboxy-
Acetyl CoA Synthetase
ATP-dependent Citrate Lyase
HMG- CoA Reductase
Acyl CoA Cholesterol
Acyl Transferase
Neutral Cholesterol Ester
I00_+7 a 98+7 88+6 71+6"
i00+5b 92+4 73_+5* 67+4*
i00+7 c i07-+/-6 108+_7 129+7"
i00+6d 122+6 84+6 82+7
Hydrolase i00+5e
Cholesterol- 7 alpha- hydroxylase i00+6 f
Acyl CoA Carboxylase
sn- Glycerol- 3 Phosphate
Acyl Transferase
Phosphatidylate
Phosphohydrolas e
Lipoprotein Lipase
100+5g
71+6 66+6* 56+5*
122+5" 125+6" 150+6"
92+5 84+5 83+6
i00+6h 115+6 109+6 101+5
I00+5 i 108+6 90+6 24+5*
100+6J 117+6 102+4 71+5"
N=6
Control
Compound" 9
25M 50tM 100M
Acetyl CoA Synthetase
ATP-dependent Citrate Lyase
HMG CoA Reductase
Acyl CoA Cholesterol
Acyl Transferase
Neutral Cholesterol Ester
I00+7a 99+6 84+5 80+5*
i00+5b 115+6 114+7 78+6*
i00+7 c 135+7" 132+6" 135+4"
100+6d i18+5 93+4 89+5
Hydrolase I00+_5 e
Cholesterol- 7- alpha-hydroxylase I00_+6 f
Acyl CoA Carboxylase
sn-Glycerol- 3- Phosphate
Acyl Transferase
Phosphatidylate
Phosphohydrolase
Lipoprotein Lipase
100+5g
94+6 89+4 88+6
205+8* 237+8* 198+7"
79+5* 75+4* 71+5"
i00_+6h 107_+6 95_+4* 85+4
I00+5 i 46+5* 31+5" 18+3"
100+6J 125+5 114+4 96+4
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Table 5 (Continued)"
N--6
Enzyme Asdsay
Compound" 1__8
Control 25tM 50tM 100M
Metal-BasedDngs
Acetyl CoA synthetase
ATP-dependent Citrate Lyase
HMG CoA Reductase
Acyl CoA Cholesterol
Acyl Transferase
Neutral Cholesterol Ester
I00_+7a 104_+7 96_+5 66_+5*
i00+5b 125+6 123+4 101+5
i00+7c 116_+5 113_+8 96+5
i00+6d 108+7 103+4 97+6
Hydrolase i00+_5e 109+5 106_+4 85_+6
Cholesterol-7-alpha-hydroxylase i00_+6 f 179_+6" 241_+5" 250_+6*
Acyl CoA Carboxylase
sn-Glycerol- 3- Phosphate
Acyl Transferase
Phosphatidylate
Phosphohydro iase
Lipoprotein Lipase
100+sg 84+3 82+6 71+4"
i00+6h 98+6 89+5 81+4"
i00+5 i 24+3* 17+2" 12+2"
100+6J 110+6 102+5 81+4"
a 28.5 mg acetyl CoA formed/g wet tissue b 30.5 mg citrate hydrolyzed/g
wet tissue c 384900 dpm cholesterol formed/g wet tissue d 224000
dpm/mg of microsomal protein e 56436 dpm/mg wet tissue f 4808 dpm/mg
protein g 537800 dpm/mg wet tissue h 302010 dpm/mg wet of microsomal
tissue i 16.7 tg Pi released/g wet tissue J 278538 dpm/g wet tissue
p _< 0.001, Student’s "t" test
DISCUSSION
These studies have shown that carboxy- and cyanoborane adducts of
cyclohexylamine and toluidine possessed good hypolipidemic acitivity in
rodents. They were approximately equal in their ability to lower serum
cholesterol and triglyceride levels in mice at 8 mg/kg/day as the
heterocyclic amine boranes. Thus, it appears the nitrogen does not have
to be in the aromatic ring to retain good hypolipidemic activity. Like
the heterocyclic amine boranes there was no significant difference
between carboxyboranes and cyanoboranes as far as their ability to lower
serum cholesterol and triglycerides after 16 days administration I.P. in
mice. However, it should be noted that compound 7_ did not afford as
good activity in rats as it did in mice, although its magnitude of serum
lipid reduction was still comparable to the standards lovastatin and
clofibrate. This type of species variation has been noted before with
boron derivatives[7]. Like many of the boron derivative these new
compounds lowered cholesterol, triglyceride and phospholipid content in
the major organs. What is most important is the fact that compound 9 was
very effective in l.wering cholesterol content within the rat aorta wall
after 14 days administration. These adducts were very impressive with
regard to their effects on lipoprotein lipid content. An ideal
hypolipidemic agent should lower cholesterol content of the VLDL and LDL
fraction since these lipoproteins are responsible for conducting
cholesterol to the peripheral tissue including the arterial walls,
whereas HDL cholesterol content should be high so that cholesterol may
be conducted back to the liver for biliary excretion. These derivatives
were able to successfully lower VLDL and LDL cholesterol content and
elevate HDL cholesterol content. In fact the elevation HDL cholesterol
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content afforded by these agents is much higher than the standards
lovastatin with a 29 increase [34] or gemfibrozil with a i04 increase
in rat HDL-cholesterol content[ll]. Supposedly, a clinical agent which
lowers LDL- and VLDL-cholesterol content but elevates HDL-cholesterol
content protects man from mycocardial infarction[ 35].
The mode of action of the derivatives on regulatory enzyme activities
involved in lipid metabolism appeared to be at site which regulated
cytoplasmic formation of acetyl-CoA for cholesterol and fatty acid
synthesis. These agents were not HMG-CoA reductase inhibitors whereas
the heterocyclic amine-carboxy- and cyanoboranes were potent inhibitors.
The amine-borane adducts of cyclohexylamine and toluidine accelerated
cholesterol-7-hydroxylase activity more than the heterocyclic amine
boranes. This would suggest that the former compounds probably
accelerate the conversion of cholesterol to bile acids theoretically
increasing cholesterol clearance from the body. These derivative
marginally inhibited, acyl-cholesterol acyl transferase activity which
should reduce cholesterol ester storage in tissues. In aorta walls this
enzyme plays a role in depositing cholesterol esters in foam cells and
increased plaque growth; thus inhibition of its activity should slow the
process. It was hoped that the agents would accelerate cholesterol
ester hydrolase activity. This enzyme breaks cholesterol esters down to
free cholesterol which can be picked up by HDL to be conducted back to
the liver via the reverse cholesterol transport mechanism for biliary
excetion of cholesterol. This enzyme level is low in man but it is
inducable by selective hypolipidemic agents to cause more clearnce of
aorta wall lipids[36]. The heterocyclic amine-boranes were able to
increase the activity of cholesterol ester hydrolaseo
The neutral lipid and triglyceride pathways were inhibited by these
derivatives at the site of phophatidylate phosphohydrolase, so that
triglyceride can not be formed from phospholipids. The other regular
enzyme of the triglyceride pathway, s__n-glycerol-3-phosphate acyl
transferase, was marginally inhibited by compounds 9 and 18. These
adducts were more potent in this respect than the heterocyclic amine
boranes. Since hepatic lipoprotein lipase activity was also inhibited by
the amine borane adducts of cyclohexylamine and toluidine, the
inhibition of these three enzyme activities should be of a magnitude to
lower triglyceride levels in the blood and tissue. Furthermore, some
accelerated loss of triglycerides occurred in the feces, although bile
excretion of triglycerides is considered to be of a small magnitude
under normal conditions.
In conclusion, the amine-borane adducts of cyclohexylamine and toluidine
maintain good hypolipidemic activity and achieve alteration in lipid
metabolism and clearance which are desirable. Further investigation is
warrented to evaluate such derivatives for clinical trails.
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